Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 22, 2022

Pyrotinib for Lapatinib-Resistant Metastatic HER2-Positive Breast Cancer

Annals of palliative medicine


Additional Info

Annals of palliative medicine
The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer
Ann Palliat Med 2022 Jan 01;11(1)332-338, C Yang, C Shangguan, G Lou, Q Qu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading